利妥昔单抗在皮肤科的非标签使用。

Off-label uses of rituximab in dermatology.

作者信息

Carr David R, Heffernan Michael P

机构信息

Division of Dermatology, Wright State University, Dayton, Ohio 45408-1445, USA.

出版信息

Dermatol Ther. 2007 Jul-Aug;20(4):277-87. doi: 10.1111/j.1529-8019.2007.00141.x.

DOI:10.1111/j.1529-8019.2007.00141.x

PMID:17970893

Abstract

Since its approval in 1997 by the FDA, rituximab has been approved for use in certain B-cell lymphomas and treatment-resistant rheumatoid arthritis. Over the past 10 years, many case reports have indicated rituximab's efficacy in a number of inflammatory conditions in dermatology. This article includes a review of the mechanism of action, dosing, and side effect profile, as well as a review of the current literature on off-label uses of the CD20(+) B-cell antagonist rituximab.

摘要

自1997年被美国食品药品监督管理局（FDA）批准以来，利妥昔单抗已被批准用于某些B细胞淋巴瘤和难治性类风湿性关节炎的治疗。在过去十年中，许多病例报告表明利妥昔单抗在皮肤科的多种炎症性疾病中具有疗效。本文包括对其作用机制、给药剂量和副作用概况的综述，以及对CD20（+）B细胞拮抗剂利妥昔单抗的非标签使用的当前文献综述。